Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-5565 (Mirogabalin) Phase 2 in Diabetic Peripheral Neuropathy
NCT01496365Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mirogabalin in diabetic peripheral neuropathy (DPN) (7 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Mean Change From Baseline to Week 5 in Average Daily Pain Score. Started Nov 2011; status: completed.
02
Drugs
mirogabalin
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT01496365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01496365.